We have also seen success in increasing survival rates and efficacy in the treatment of animal tumors whenДЄmpligenВ® is used in combination with checkpoint blockade therapies. Get the latest from our blog.ДЄIM ImmunoTechвЂ™s flagship products include AmpligenВ® (Rintatolimod), a developmental first-in-class drug of large macromolecular RNA molecules.ДЄmpligenВ® has in the clinic demonstrated the potential for standalone efficacy in a number of solid tumors. ДЄIM ImmunoTech is engaged in the clinical development of new drug entities for the treatment of seriously debilitating disordersДЄIM ImmunoTech is committed to providing up to date information to shareholders, analysts, and potential investors. We are committed to a focused business plan oriented toward finding senior co-development partners with the capital andД®xpertise needed to commercialize the many potential therapeutic aspects of AmpligenВ® and our FDA-approved drug AlferonВ® N. facility in New Brunswick, NJ with the objective of producing AmpligenВ® and AlferonВ®. Or recurring external Condylomata Acuminata/genital warts (GW) in patients 18 years of age or older. for the intralesional treatment of refractory (resistant to other treatment) We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acidsДЄnd natural interferon to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases.ДЄIM ImmunoTechвЂ™s flagship products include AmpligenВ® (Rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon N InjectionВ® (Interferon Alfa-N3).ДЄmpligenВ® represents an RNA being developed for globally important cancers, viral diseases and disorders of the immune system.ДЄmpligenВ® is also being evaluated for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).ДЄlferon N InjectionВ® is approved for a category of STD infection and patients that are intolerant to recombinant interferon in Argentina.ДЄlferon is the only natural-source, multi-species alpha interferon currently approved for sale in the U.S. is an immuno-pharma company headquartered in Ocala, Florida and focused on the research and development of therapeutics to treat multiple types of cancers,ДЄs well as immune-deficiency disorders.

Aim stocktwits